



Discodermolide
A Synthetic Challenge




Nicole Goodwin
MacMillan Group Meeting
April 21, 2004

Discodermolide
Isolation and Biological Activity



- Isolated in 1990 by the Harbor Branch Oceanographic Institution from the Caribbean deep-sea sponge *Discodermia dissoluta*
- Not practical to produce discodermolide from biological sources
 - 0.002% (by mass) isolation from frozen sponge
 - must be deep-sea harvested at a depth in excess of 33 m
- Causes cell-cycle arrest at the G₂/M phase boundary and cell death by apoptosis
- Member of an elite group of natural products that act as microtubule-stabilizing agent and mitotic spindle poisons
 - Taxol, epothilones A and B, sarcodictyin A, eleutherobin, laulimalide, FR182877, peloruside A, dictyostatin
- Effective in Taxol-resistant carcinoma cells
 - presence of a small concentration of Taxol amplified discodermolide's toxicity by 20-fold
 - potential synergies with the combination of discodermolide with Taxol and other anticancer drugs
- Licensed by Novartis from HBOI in 1998 as a new-generation anticancer drug











Discodermolide
Isolation and Biological Activity



The chemical structure of Discodermolide is shown, featuring a complex polycyclic system with various functional groups including hydroxyl (-OH), methyl (-Me), and carbonyl (-C=O) groups, along with a terminal alkyne group.

- Considerable synthetic effort to produce discodermolide because of dearth of biological supply
 - Taxol is semi-synthesized from an intermediate extracted from the European Yew tree
 - the epothilones are obtained from fermentation
- Several total syntheses and numerous fragment syntheses
 - 1993 - Schriener
 - 1995 - Smith
 - 1998 - Smith, second generation
 - 1997 - Myles (UCLA)
 - 1998 - Marshall (UVa)
 - 2000 - Paterson
- Novartis synthesis is a combination these total syntheses
 - Smith - fragment syntheses from a common precursor (CP)
 - Marshall - β -alkyl Suzuki coupling of C14 to C15
 - Paterson - endgame

















Paterson 2001
Alternate Syn Aldol Approach is Unsuccessful





Paterson 2001
Finishing the C₉ to C₂₄ Fragment











Smith 1995
Synthesis of Common Precursor




- Smith's approach to proceed from a common precursor was adopted by Novartis
- Utilizes Evans oxazolidinone Aldol chemistry to set the stereotriad




- Yield of norephedrine-based Aldol was 64-70% on 60-70 g scales, 55% for all 4 steps with recrystallization, auxiliary recovery was 80-90%



* 1. PMBO(C=NH)CCl₃, PPTs. 2. LAH. 3. Swern.

Smith 1995
Elaboration of Common Precursor




- Polypropionate elaboration for C₁₅-C₂₁
- A subsequent Evans *syn* Aldol - one diastereomer for stereopentad






Smith 1995
Wittig Olefination for Cis C_8-C_9 Olefin

■ Problems in making alkyl iodide




■ Turn to model systems and solvent effects



■ More polar solvents promote cyclization (MeCN or MeCN/Et₂O), less polar solvents favor iodide


Smith 1995
Wittig Olefination for Cis C_8-C_9 Olefin



■ High pressure necessary to form Wittig







- addition of base necessary to absorb HI that forms and causes decomposition of starting iodide

■ Wittig reaction proceeds smoothly










Diastereoselective Additions of Chiral Allenyl Stannanes

■ Chiral aldehyde additions



(R/S) - R	conditions	yield %	A:B	C:D
(S) - CH ₂ OAc	A	95	68:32	>99:1
	B	97		
(R) - CH ₂ OAc	A	97	97:3	1:99
	B	97		
(S) - Et	A	92	87:13	>99:1
	B	98	>99:1	
(R) - Et	A	89	>99:1	1:99
	B	95		

A: BF₃·OEt₂, CH₂Cl₂, -78 °C.
 B: MgBr₂·OEt₂, CH₂Cl₂, -23 to 0 °C


■ No efficient ways to produce *anti,anti* B

■ Selectivity governed by Felkin-Ahn (for B) or Cram-chelation (for Mg) transition states


■ Anti products are rarely observed with crotylstannanes

Marshall, J. A.; Wang, X.-j. *J. Org. Chem.* **1992**, 57, 1242.

Diastereoselective Additions of Chiral Allenyl Stannanes Transition State Analysis for Non-Chelating Case with BF₃OEt₂







■ Felkin-Ahn TS for (S)-allene is complicated by conformation mobility of the aldehyde - selectivity degradation



(R/S) - R	conditions	yield %	A:B	C:D
(S) - CH ₂ OAc	A	95	68:32	>99:1
	B	97	>99:1	
(R) - CH ₂ OAc	A	97	97:3	1:99
	B	97		


A: BF₃·OEt₂
 B: MgBr₂·OEt₂






Diastereoselective Additions of Chiral Allenyl Stannanes
Inversion of Allene Stereochemistry with SnCl_4

■ Solvent has a pronounced effect




■ Cyclic transition states are very selective, and **1** is from aldehyde epimerization




Marshall, J. A.; Perkins, J. F.; Wolf, M. A. *J. Org. Chem.* **1995**, *60*, 5556.

Diastereoselective Additions of Chiral Allenyl Stannanes
Inversion of Allene Stereochemistry with SnCl_4

■ Mechanism of allene rearrangement



■ Propargyl stannane intermediate observed experimentally




■ Reproducibility can be problematic with SnCl_4 - InI_3 or SnBuCl_3 also do allene inversion but have decreased selectivity
(Marhsall, J. A.; Palovich, M. R. *J. Org. Chem.* **1997**, *62*, 2001.)


■ Allenylsilanes can also be used with TiCl_4 - all 4 stereotriads can be access by choice of chelating or non-chelating group on aldehyde
(Marhsall, J. A.; Maxson, K. *J. Org. Chem.* **2000**, *65*, 603.)

Diastereoselective Additions of Chiral Allenyl Stannanes
Summary

■ Access to all 4 stereotriads from one allenyl stannane using reagent control




Marshall 1998
Retrosynthesis




Marshall, J. A.; Johns, B. A. *J. Org. Chem.* **1998**, *63*, 7885.

Marshall 1998
Stereotriad Syntheses




■ C₂-C₄ and C₁₀-C₁₂ stereotriad from new allenylzinc addition (Marshall *J. Org. Chem.* **1998**, 63, 3812)

- SnCl₄ methodology proved to be problematic in reproducibility, BuSnCl₃ gave 48% yield
- did not desire to use InI₃ or InBr₃ in large scale syntheses




■ C₁₆-C₁₈ stereotriad from allenylstannane addition with BF₃OEt₂




Marshall, J. A.; Johns, B. A. *J. Org. Chem.* **1998**, 63, 7885.

Marshall 1998
Stereotriad Syntheses




■ C₂-C₄ and C₁₀-C₁₂ stereotriad from new allenylzinc addition (Marshall *J. Org. Chem.* **1998**, 63, 3812)

- SnCl₄ methodology proved to be problematic in reproducibility, BuSnCl₃ gave 48% yield
- did not desire to use InI₃ or InBr₃ in large scale syntheses




Marshall 1998
Approach to Tri-substituted olefin




■ A new approach to olefin formation - β -alkyl Suzuki coupling

■ First must selectively form (*Z*)-vinyl iodide - Wittig reagent


- Wittig reagent is low yielding and not as selective as other methods but amenable for large scale synthesis
- Paterson's selenium reagent is toxic
- Panek uses a large excess of Schwartz's reagent



Panek:




■ Marshall:




Marshall, J. A.; Johns, B. A. *J. Org. Chem.* 1998, 63, 7885.

Marshall 1998
Approach to Tri-substituted olefin




■ A new approach to olefin formation - β -alkyl Suzuki coupling




■ used by Novartis on a 2.5 kg scale


■ Smith's Negishi coupling gave several inseparable by-products on large scale



(+)-Discodermolide
8 steps
23 steps (linear)
5.4% overall yield



Marshall, J. A.; Johns, B. A. *J. Org. Chem.* 1998, 63, 7885.



Summary *Discodermolide*

- Several total syntheses and numerous formal syntheses
- Smith and Paterson and Marshall approaches were combined for the commercial synthesis by Novartis
- Other approaches detail novel ways to access stereotriads or stereopentad.
 - none are as efficient as the approaches described here
 - Schrieber, Myles, and Smith (2nd generation) utilizes lewis acid-mediated crotylations with allylsilanes or allyl stannanes - not useful for larger scale
- There is no practical, original way to set polypropionates for discodermolide
- Large scale preparation of discodermolide will allow for significant testing for anti-cancer activity and other health issues

Useful References

Discodermolide

■ Novartis synthesis

- Mickel, S. J. et al. *Organic Process Research & Development*. **2004**, *8*, 92-100.
Mickel, S. J. et al. *Organic Process Research & Development*. **2004**, *8*, 101-106.
Mickel, S. J. et al. *Organic Process Research & Development*. **2004**, *8*, 107-112.
Mickel, S. J. et al. *Organic Process Research & Development*. **2004**, *8*, 113-121.
Mickel, S. J. et al. *Organic Process Research & Development*. **2004**, *8*, 122-130.

■ Paterson synthesis

- Paterson, I.; Florence, G. J.; Gerlach, K.; Scott, J. P.; Sereinig, N. *J. Am. Chem. Soc.* **2001**, *123*, 9535-9544.
Paterson, I.; Delgado, O.; Florence, G. J.; Lyothier, I.; Scott, J. P.; Sereining, N. *Org. Lett.* **2003**, *5*, 35-38.

■ Smith synthesis

- Smith, A. B.; Qiu, Y.; Jones, D. R.; Kobayashi, K. *J. Am. Chem. Soc.* **1995**, *117*, 12011-12012.
Smith, A. B. III; et al. *J. Am. Chem. Soc.* **2000**, *122*, 8654-8664.
Smith, A. B. III; Freeze, B. S.; Brouard, I.; Hirose, T. *Org. Lett.* **2003**, *5*, 4405.

■ Marshall synthesis

- Marshall, J. A.; Johns, B. A. *J. Org. Chem.* **1998**, *63*, 7885-5892.
Marshall, J. A.; Lu, Z.-H.; Johns, B. A. *J. Org. Chem.* **1998**, *63*, 817-823.

■ Myles synthesis

- Harried, S. S.; Yang, G.; Strawn, M. A.; Myles, D. C. *J. Org. Chem.* **1997**, *62*, 6098-6099.
Harried, S. S.; Lee, C. P.; Yang, G.; Lee, T. I. H. *J. Org. Chem.* **2003**, *68*, 6646-6660.

■ Scrieber synthesis

- Nerenberg, J. B.; Hung, D. T.; Somers, P. K.; Schreiber, S. L. *J. Am. Chem. Soc.* **1993**, *115*, 12621-12622.
Hung, D. T.; Nerenberg, J. B.; Schreiber, S. L. *J. Am. Chem. Soc.* **1996**, *118*, 11054-11080.